Instrument overview

MRVIMaravai LifeSciences Holdings

StockNasdaqUnited StatesHealth careEU retail: available

+2.9% today · +163.2% over a year

No score: too little data.

Trend: among the best of its peers; Quality: among the weakest. No dividend.

Maravai LifeSciences Holdings (MRVI) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €1.1B. Over the past 12 months the price changed by +163.2%, with an annualised volatility of 67% and a largest fall of 30%. Hard red flags in our rules-based screen: Financial distress.

Not scored: not enough data for a fair comparison.

Factor scores

Profitability, balance-sheet safety, growth and capital discipline versus peers. More in the glossary →better than 15% of peers
Price trend over the last 12 and 6 months (excluding the last month) and distance from the 52-week high. More in the glossary →better than 95% of peers
Lower price swings, lower market sensitivity (beta) and shallower drawdowns score higher. More in the glossary →better than 22% of peers

Percentiles within the peer group (100 = the best of its peers); dividend safety in points.

Main drivers

  • Gross profit growth / assets (5 y)weighs on the score · better than 3% of peers
  • 12-month trend (ex last month)supports the score · better than 91% of peers
  • Gross profit / assetsweighs on the score · better than 4% of peers

Red flags and notes

  • Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
  • Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
  • Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.

Price chart

Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.

Key metrics

Valuation

P/B
6.1
Market cap (EUR)
€1.1B

Profitability and debt

Return on equity
−32.9%
Return on invested capital
−41.0%
Gross margin
34.9%

Dividends

Dividend yield
0.00%
Years of dividend growth
0

Returns and risk

1 day
+2.9%
1 month
+11.4%
1 year
+163.2%
Volatility, 1 yr
66.9%
Max drawdown, 1 yr
−29.6%
Beta
1.10

Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.

Similar companies

Same sector and region, closest in market value.

ENOVEnovis Corporation2/100.0%−33.3%
TDOCTeladoc Health Inc3/100.0%−17.7%
USPHUS Physical Therapy Inc4/102.1%−2.7%
INNVInnovAge Holding Corp.7/100.0%79.1%
SNDXSyndax Pharmaceuticals Inc.1/100.0%6.0%
STAASTAAR Surgical Co2/100.0%−9.4%
LBRXLB Pharmaceuticals Inc—/100.0%140.4%
OMEROmeros Corporation1/100.0%124.6%

News and filings

What the marks mean
  • FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
  • Media reportA headline from a named media outlet. We link to it and do not check it.
  • RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.

Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.

Score changes in the last 12 months

Every published rating and change, logged when it was published (EU Market Abuse Regulation).

Show the log: 1 entry
DateEventBalancedGrowth · IncomeWarningsPrice at publication
First rating —/10 — · — Available with Invest Pro

Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.